Verve-102's 82% Approval Odds: Am I Missing Something?

I've been staring at the Kalshi market for VERVE-102's FDA approval, and honestly, the 82% YES price is making my eyebrows climb right off my face. Eighty-two percent! That means the crowd is overwhelmingly confident that Verve Therapeutics' gene-editing therapy will get the green light from the FDA before January 1, 2035. As someone who watches these markets religiously, that number feels audacious for a drug in this stage of development.

For those of you who might not be deep into biotech, VERVE-102 is a fascinating candidate. It's an investigational gene-editing medicine designed to permanently turn off the PCSK9 gene in the liver, aiming to lower LDL cholesterol for people with heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic cardiovascular disease (ASCVD). Basically, it’s a potential one-time treatment for a condition that currently requires lifelong medication for millions. The scientific promise is huge, no doubt about it. The idea of a permanent fix for high cholesterol is, on paper, incredibly appealing, especially for patients who struggle with existing therapies.

But let's talk about that 82%. What does it really mean? It means if you bet $82 now on YES, you'd get $100 back if it gets approved. Conversely, if you bet $18 on NO, you'd get $100 if it doesn't. My first thought when I saw that price was, "Are people factoring in how brutal and long the drug approval process is?" The market has traded 282 contracts, and there are 61 contracts currently open, suggesting a decent, albeit not massive, level of conviction and activity. These aren't just random guesses; there's real money behind these probabilities.

Here’s the thing you need to know about VERVE-102: it’s currently in a Phase 1 clinical trial, called Heart-1. Phase 1 is all about safety and dosage in a small group of people. While early data from Heart-1 has shown promising signs of LDL cholesterol reduction and a tolerable safety profile, we are still a very, very long way from FDA approval. Historically, the success rate for drugs entering Phase 1 to actually achieving FDA approval is depressingly low – often cited in the single digits, especially for novel modalities like gene editing. Even if it gets through Phase 2 and 3, which are much larger and more rigorous trials, there are still so many hurdles.

Consider the timeline. The market closes on January 1, 2035. That’s about 11 years from now. While 11 years might seem like a lot of time for drug development, it's actually not that long for a gene-editing therapy starting at Phase 1. Each phase of a clinical trial can take years, and that's assuming everything goes perfectly. Delays in enrollment, unexpected side effects, or even just statistical endpoints not being met can push timelines back significantly, or even kill a drug outright. And we haven't even mentioned the regulatory scrutiny that a first-in-class gene-editing therapy would face. The FDA is understandably cautious with these groundbreaking treatments, and rightly so.

So, where would I put my money? While the science behind VERVE-102 is exciting and certainly holds immense potential, I find it hard to justify an 82% approval probability right now. The market appears to be heavily weighting the potential upside and the long-term horizon, perhaps underestimating the sheer difficulty of navigating the clinical trial gauntlet for a gene-editing drug. My read on this is that the enthusiasm for gene editing and the unmet need for HeFH patients might be creating an overly optimistic price here.

If I were trading this, I'd be looking closely at the NO side. Eighteen percent seems remarkably low for the inherent risks involved in taking a Phase 1 gene therapy all the way to market in 11 years. There's a lot that can go wrong, and even a small setback could send those odds plummeting. I'm genuinely curious to see if this market adjusts as more data emerges from the Heart-1 trial and, eventually, as it (hopefully) progresses to later phases. For now, I'm watching that 82% and wondering if it's priced for perfection in a world that's anything but.